Serotonin-norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressants that block the reuptake of both serotonin and norepinephrine in the body. They are taken to treat depression, ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority ...

The FDA has started a priority review of Otsuka Pharma's triple-acting drug for attention-deficit hyperactivity disorder ...

Ampreloxetine, an investigational, once-daily, selective norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with ...

Esketamine combined with a serotonin-norepinephrine reuptake inhibitor (SNRI) for treatment-resistant depression (TRD) was linked to significantly lower rates of several adverse outcomes than ...

AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...

Please provide your email address to receive an email when new articles are posted on . Viloxazine is a noradrenergic/norepinephrine reuptake inhibitor, and trazodone ...